Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Future OncologyOpen Access

Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study

View Full Paper
Ask AI
Bookmark
Share

Authors

YAYusuke ArugaNovartis (Switzerland)WHWataru HongoNovartis (Switzerland)WLWeizhe LuNovartis (Switzerland)

Discussion

Loading...

Member takes

Implication

Observational study evaluates ruxolitinib's safety and effectiveness in myelofibrosis, highlighting adverse drug reactions.

Key Points

  • Ruxolitinib shows reasonable effectiveness in myelofibrosis, with no new safety concerns found.
  • 67.7% of patients experienced adverse drug reactions, primarily anemia and decreased platelet count.
  • Median overall survival was not reached, indicating the treatment's potential benefits require further analysis.
  • Spleen responses and symptom improvement were observed in 26.2% and 52.0% of patients at 6 months.

Cite This Study

Aruga et al. (2025) studied this question.

synapsesocial.com/papers/68c1d60654b1d3bfb60f9645https://doi.org/10.1080/14796694.2025.2550924
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis2012 · 2,108 citations
  2. 2The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies2016 · 91 citations
  3. 3Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses2017 · 307 citations
  4. 4JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis2012 · 1,834 citations
  5. 5Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety2023 · 61 citations